Opinion|Videos|October 7, 2024

PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

Author(s)Neal Shore, MD, FACS

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.

Episodes in this series

EP. 1 Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

EP. 1 Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

EP. 2 PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP. 2 PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

EP. 3 Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

EP. 3 Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials

EP. 4 Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

EP. 4 Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging

EP. 5 Treatment Considerations for PSMA-Positive mCRPC Patients

EP. 5 Treatment Considerations for PSMA-Positive mCRPC Patients

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC